Zoetis to Sell Medicated Feed Additive Portfolio
USAgNet - 05/05/2024
Zoetis Inc. and Phibro Animal Health Corporation announced that they have entered into a definitive agreement where Phibro Animal Health will acquire Zoetis' medicated feed additive (MFA) product portfolio, certain water soluble products and related assets
for $350 million, subject to customary closing adjustments. This transaction is expected to be complete in the second half of calendar year 2024.
Both Zoetis and Phibro Animal Health have a longstanding commitment to the production animal health sector. The acquired product portfolio, which generated approximately $400 million in revenue in 2023, is comprised of more than 37 product lines that are
sold in approximately 80 countries. Also included in the agreement are six manufacturing sites, four in the U.S., one in Italy and one in China. More than 300 Zoetis colleagues who support manufacturing, distribution and commercial activities are expected to
transition to Phibro Animal Health.
This transaction demonstrates Zoetis' disciplined capital allocation strategy to focus its investments on solutions for animal health, productivity and sustainability. With this divestiture, Zoetis can focus its livestock investments in other solutions, including vaccine,
biologic and genetic programs.
- Economist: Age of U.S. Farmers is Not a Problem
- China Approves GM Wheat Crops
- Rabobank: Global Pork Production Returns to Profitability
- NCGA Hosts Celebration of Women at Event
- Elanco Reports Lower Revenue, Net Income
- Florida Bans Sale of Lab-Grown Meat
- House Ag Chair Releases 2024 Farm Bill Overview